Preparing regenerative therapies for clinical application: proposals for responsible translation

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Nelson TJ, Behfar A, Terzic A. Strategies for therapeutic repair: The “R³” regenerative medicine paradigm. Clin. Trans. Sci. 1(2), 168–171 (2008).
  MedlineGoogle Scholar
• 2 Terzic A, Nelson TJ. Regenerative medicine: advancing health care 2020. J. Am. Coll. Cardiol. 55(20), 2254–2257 (2010).
  MedlineGoogle Scholar
• 3 Terzic A, Nelson TJ. Regenerative medicine primer. Mayo Clin. Proc. 88(7), 766–775 (2013). •• Highlights Mayo Clinic's vision for the development of regenerative therapies.
  MedlineGoogle Scholar
• 4 National Academies of Sciences, Engineering, and Medicine. Exploring the state of the science in the field of regenerative medicine: challenges of and opportunities for cellular therapies: proceedings of a workshop. The National Academies Press, DC, USA (2017). https://doi.org/10.17226/24671.
  Google Scholar
• 5 Johnson S, Atala A. Regeneology: time for a new specialty? Stem Cell Transl. Med. 8(1), 4–6 (2019). http://dx.doi.org/10.1002/sctm.18-0101. •• Considers regenerative medicine as a new specialty.
  MedlineGoogle Scholar
• 6 Trounson A, DeWitt ND, Feigal EG. The alpha stem cell clinic: a model for evaluating and delivering stem cell-based therapies. Stem Cells Transl. Med. 1(1), 9–14 (2012). • Describes the California Institute of Regenerative Medicine's Alpha Stem Cell Clinic model.
  MedlineGoogle Scholar
• 7 California Institute for Regenerative Medicine (CIRM). About alpha clinics (2018). www.cirm.ca.gov/patients/alpha-clinics-network/about.
  Google Scholar
• 8 Kleiderman E, Boily A, Hasilo C, Knoppers BM. Overcoming barriers to facilitate the regulation of multi-centre regenerative medicine clinical trials. Stem Cell Res. Ther. 9, 307–316 (2018). •• Outlines barriers to performing large scale, multi-center clinical trials.
  MedlineGoogle Scholar
• 9 US FDA. Statement from FDA Commissioner Scott Gottlieb, MD on FDA's comprehensive new policy approach to facilitating the development of innovative regenerative medicine products to improve human health (2017). www.fda.gov/newsevents/newsroom/pressannouncements/ucm585342.htm.
  Google Scholar
• 10 US FDA. 21^st Century Cures Act (2018). www.fda.gov/regulatoryinformation/lawsenforcedbyfda/significantamendmentstothefdcact/21stcenturycuresact/default.htm.
  Google Scholar
• 11 Surani SH, Levine AD. State performance in pluripotent and adult stem cell research, 2009–2016. Regen. Med. 13(3), 309–320 (2018).
  CASGoogle Scholar
• 12 Ronfard V, Vertès AA, May MH, Dupraz A, van Dyke ME, Bayon Y. Evaluating the past, present and future of regenerative medicine: a global view. Tissue Eng. Part B Rev. 23(2), 199–209 (2017). • Updated evaluation of regenerative medicine therapies.
  MedlineGoogle Scholar
• 13 Siprashvili Z, Nguyen NT, Gorell ES et al. Safety and wound outcomes following genetically corrected autologous epidermal grafts in patients with recessive dystrophic epidermolysis bullosa. JAMA 1316(17), 1808–1817 (2016).
  Google Scholar
• 14 Hirsch T, Rothoeft T, Teig N et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature 551, 327–332 (2017).
  Medline CASGoogle Scholar
• 15 Holmes Iv JH, Molnar JA, Carter JE et al. A comparative study of the ReCell^® device and autologous spit-thickness meshed skin graft in the treatment of acute burn injuries. J. Burn Care Res. 39(5), 694–702 (2018).
  MedlineGoogle Scholar
• 16 US FDA. FDA approval brings first gene therapy to the United States (2017). www.fda.gov/newsevents/newsroom/pressannouncements/ucm574058.htm.
  Google Scholar
• 17 US FDA. FDA approves CAR-T cell therapy to treat adults with certain types of large B-cell lymphoma (2017). www.fda.gov/newsevents/newsroom/pressannouncements/ucm581216.htm.
  Google Scholar
• 18 Jain MD, Davila ML. Concise review: emerging principles from the clinical application of chimeric antigen receptor T cell therapies for B cell malignancies. Stem Cells 36(1), 36–44 (2018).
  MedlineGoogle Scholar
• 19 European Medicines Agency. First stem-cell therapy recommended for approval in EU (2014). www.ema.europa.eu/en/news/first-stem-cell-therapy-recommended-approval-eu.
  Google Scholar
• 20 Daniel E. EU approves first allogenic therapy for Crohn's disease. Pharmaceutical Technology (2018). www.pharmaceutical-technology.com/news/eu-allogenic-crohns-alofisel/.
  Google Scholar
• 21 Houdek MT. Do early results of proximal humeral allograft-prosthetic composite reconstructions persist at 5-year followup? Clin. Orthop. Relat. Res. doi:10.1097/CORR.0000000000000417 (2018) (Epub ahead of print).
  Google Scholar
• 22 Dai WL, Zhou AG, Zhang H, Zhang J. Efficacy of platelet-rich plasma in the treatment of knee osteoarthritis: a meta-analysis of randomized controlled trials. Arthroscopy 33(3), 659–670 (2017).
  MedlineGoogle Scholar
• 23 Gentile P, Garcovich S, Bielli A, Scioli MG, Orlandi A, Cervelli V. The effect of platelet-rich plasma in hair regrowth: a randomized placebo-controlled trial. Stem Cell Transl. Med. 4(11), 1317–1323 (2015).
  Medline CASGoogle Scholar
• 24 A futile cycle in cell therapy. Nat. Biotechnol. 35(4), 291 (2017).
  MedlineGoogle Scholar
• 25 Abbot S, Agbanyo F, Ahlfors JE et al. Report of the international conference on manufacturing and testing of pluripotent stem cells. Biologicals 56, 67–83 (2018).
  MedlineGoogle Scholar
• 26 Kamenova K, Caulfield T. Stem cell hype: media portrayal of therapy translation. Sci. Transl. Med. 7(278), 278ps4 (2015).
  MedlineGoogle Scholar
• 27 Sipp D, Caulfield T, Kaye J et al. Marketing of unproven stem cell-based interventions: a call to action. Sci. Transl. Med. 9(397), pii: eaag0426 (2017).
  MedlineGoogle Scholar
• 28 Turner L. The US direct-to-consumer marketplace for autologous stem cell interventions. Perspect. Biol. Med. 61(1), 7–24 (2018).
  MedlineGoogle Scholar
• 29 Knoepfler PS. The stem cell hard sell: report from a clinic's patient recruitment seminar. Stem Cell Transl. Med. 6(1), 14–16 (2017).
  MedlineGoogle Scholar
• 30 Scott CT. The case for stem cell counselors. Stem Cell Rep. 4(1), 1–6 (2015).
  MedlineGoogle Scholar
• 31 Master Z, Robertson K, Frederick D, Rachul C, Caulfield T. Stem cell tourism and public education: the missing elements. Cell Stem Cell 15(3), 267–270 (2014).
  Medline CASGoogle Scholar
• 32 US FDA. Same surgical procedure exception under 21 CFR 1271.15(b): questions and answers regarding the scope of the exception, guidance for industry (2017). www.fda.gov/downloads/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/tissue/ucm419926.pdf.
  Google Scholar
• 33 Shapiro SA, Kazmerchak SE, Heckman MG, Zubair AC, O'Connor MI. A prospective, single-blind, placebo-controlled trial of bone marrow aspirate concentrate for knee osteoarthritis. Am. J. Sports Med. 45(1), 82–90 (2017).
  MedlineGoogle Scholar
• 34 Shapiro SA, Arthurs JR, Heckman MG et al. Quantitative T2 MRI mapping and 12-month follow-up in a randomized, blinded, placebo controlled trial of bone marrow aspiration and concentration for osteoarthritis of the knees. Cartilage doi:10.1177/1947603518796142 (2018) (Epub ahead of print).
  MedlineGoogle Scholar
• 35 Hay M, Thomas DW, Craighead JL, Economides C, Rosenthal J. Clinical development success rates for investigational drugs. Nat. Biotechnol. 32, 40–45 (2014).
  Medline CASGoogle Scholar
• 36 Thomas DW, Burns J, Audette J, Carroll A, Dow-Hygelund C, Hay M. Clinical development success rates 2006–2015. BIO Industry Analysis (2016). www.bio.org/sites/default/files/Clinical%20Development%20Success%20Rates%202006-2015%20-%20BIO,%20Biomedtracker,%20Amplion%202016.pdf.
  Google Scholar
• 37 Downing NS, Shah ND, Aminawung JA et al. Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 317(18), 1854–1863 (2017).
  MedlineGoogle Scholar
• 38 US FDA. CBER Regenerative Medicine Advanced Therapy (RMAT) designation requests (2018). www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm587021.htm.
  Google Scholar
• 39 US FDA. Use of real-world evidence to support regulatory decision-making for medical devices, Guidance for Industry and Food and Drug Administration Staff (2017). www.fda.gov/downloads/medicaldevices/deviceregulationandguidance/guidancedocuments/ucm513027.pdf. • Discussees US FDA's regulatory perspectives on the use of real-world evidence for regulatory decision making.
  Google Scholar
• 40 Bipartisan Policy Center. Using real-world evidence to accelerate safe and effective cures: advancing medical innovation for a healthier America (2016). http://cdn.bipartisanpolicy.org/wp-content/uploads/2016/06/BPC-Health-Innovation-Safe-Effective-Cures.pdf.
  Google Scholar
• 41 Registries for Evaluating Patient Outcomes: A User's Guide (Third Edition). Gliklich R, Dreyer N, Leavy M (Eds). Agency for Healthcare Research and Quality, Rockville, MD, USA (2014). www.effectivehealthcare.ahrq.gov/sites/default/files/related_files/registries-guide-3rd-edition-vol-2-140430.pdf.
  Google Scholar
• 42 Davis J. Europe's GDPR privacy law is coming: here's what US health orgs need to know. Healthcare IT News (2018). www.healthcareitnews.com/news/europes-gdpr-privacy-law-coming-heres-what-us-health-orgs-need-know.
  Google Scholar
• 43 International Society for Cell and Gene Therapy (ISCT). The ISCT Presidential Task Force (PTF) on the use of unproven and/or unethical cell and gene therapy (2018). www.isct-unprovencellulartherapies.org.
  Google Scholar
• 44 ISSCR. Guidelines for stem cell research and clinical translation (2016). www.isscr.org/docs/default-source/all-isscr-guidelines/guidelines-2016/isscr-guidelines-for-stem-cell-research-and-clinical-translationd67119731dff6ddbb37cff0000940c19.pdf?sfvrsn=4. • Internationally recognized guidelines for the responsible translation of stem cell-based interventions.
  Google Scholar
• 45 AABB. Center for cellular therapies (2018). www.aabb.org/aabbcct/Pages/default.aspx
  Google Scholar
• 46 Chu CR, Rodeo S, Bhutani N et al. Optimizing clinical use of biologics in orthopedic surgery: consensus recommendations from the 2018 AAOS/NIH U-13 Conference. J. Am. Acad. Orthop. Surg. 27(2), e50–e63 (2019).
  MedlineGoogle Scholar
• 47 American Thoracic Society. Unproven stem cell treatments for lung disease – an emerging public health problem. Am. J. Respir. Crit. Care Med. 195, 13–14 (2017).
  MedlineGoogle Scholar
• 48 Mihalko WM, Golish SR, Watson JT. Stem cell centers in the United States: patients should proceed with caution. American Academy of Orthopedic Surgeons (2018). www.aaos.org/News/DailyEdition2018/Friday/004/?ssopc=1.
  Google Scholar